Continuing cotrimoxazole in children on ART reduces the risk of hospitalisation

Mutsa Bwakura-Dangarembizi presenting at CROI 2013.
Carole Leach-Lemens
Published: 06 March 2013

Children on ART for more than two years who continued taking daily cotrimoxazole had significantly fewer hospitalisations for malaria as well as for non-malarial infections (notably pneumonia, sepsis and meningitis), compared to children who stopped this treatment, researchers from Uganda and Zimbabwe reported at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) in Atlanta this week.

The benefits of continued use of cotrimoxazole persisted across all age groups and CD4 counts.

The researchers advocate the continued use of cotrimoxazole long term in children and adolescents on ART in resource-poor countries, and recommend that current guidelines be revised accordingly. However, they caution, for this to happen health care systems and supply-chain logistics must be strengthened to avoid stock-outs.

This is a sub-study of the ARROW trial reported earlier this week, which showed that children did as well on antiretroviral therapy without routine laboratory monitoring of CD4 cell counts or drug side-effects as those who received regular monitoring over four years of follow-up. The trial recruited over 1200 symptomatic HIV-infected infants and children in Uganda and Zimbabwe. 

Cotrimoxazole is a cheap, widely available antibiotic, easy to use with no adverse side-effects. It is commonly used in low- and middle-income countries for a wide range of fungal and bacterial infections. Cotrimoxazole prophylaxis is known to reduce death and disease – including malaria, pneumonia and diarrhoea – in HIV-positive adults and children before they start ART.

The adult DART study showed the benefits of continuation of cotrimoxazole for the first 18 months on ART. Other adult studies are ongoing. 

However, the long-term effect of cotrimoxazole in children on ART is unknown; there are no trials on discontinuation of cotrimoxazole in children and no data from Africa.

While current World Health Organization (WHO) guidelines on cotrimoxazole prophylaxis recommend cotrimoxazole continuation, they also state that: “Children over 5 years of age with good adherence after more than six months on ART, full clinical recovery and CD4 counts over 350 cells/mm3, may discontinue cotrimoxazole.”

The researchers chose to look at whether stopping daily cotrimoxazole in children over three years of age, and on ART for at least 96 weeks, had a similar outcome determined by hospitalisation or death as those continuing daily cotrimoxazole. Co-primary endpoints were hospitalisation or death (efficacy) and any grade 3 or 4 adverse events (AEs; safety).

A total of 758 children from the ARROW trial with a median of 2.1 years on ART (interquartile range IQR1.8-2.2) were randomised to stop (382) or continue (376) daily cotrimoxazole. Eligibility included being over three years of age, on ART for more than 96 weeks, currently on daily cotrimoxazole, using an insecticide-treated bed net if living within a malaria-endemic area and having no previous pneumocystis jirovecii pneumonia (PCP) episodes.

Of note, over 1000 children were eligible and approached for consent. However, caregivers of 25% of these children declined because they had faith in cotrimoxazole, having used it for their children before ART became available.

At randomisation, the median age was seven (IQR: 4-11) years and the CD4 percentage was 33 (IQR: 26-29).  The two groups were similar in age, sex, CD4 percentage and cell count, and years on ART.  

The improvement  in immune status was substantial when compared to the time of enrolment in the trial. Median follow-up was 2.1 years; nine children withdrew or were lost. Adherence to the strategy was very high in both groups.

Among children who stopped cotrimoxazole there was a 60% increase in hospitalisation or death, hazard ratio HR: 1.57, 95%CI: 1.09-2.26, p=0.007. Age, sex, clinically indicated compared to routine CD4 test monitoring, and facility attended made no difference to the outcomes.

While there was some variation in cotrimoxazole effect by CD4 count, the benefits of continuing cotrimoxazole were greatest in those with CD4 percentage was equal to or above 30%, HR: 2.15, 95% CI: 1.30-3.54; 19% who stopped compared to 10% who continued were hospitalised.

There were few deaths, with no real difference between the two groups:  2/382 (0.5%)amongst those those who stopped and 3/376 (0.8%) of those who continued, respectively.

The primary endpoint was driven by hospitalisation. Among those who stopped cotrimoxazole, the increased number of hospitalisations for both malaria (49 compared to 20) and non-malarial infections (53 compared to 25; notably pneumonia, sepsis and meningitis) was quite considerable. 

Among children who stopped cotrimoxazole, there was a two-fold increased risk for getting malaria, HR: 2.10, 95% CI: 1.43-3.09, p<0.0001. In addition, the parasite density was also higher among those who stopped cotrimoxazole and went on to develop malaria.

The overall risks for grade 3 and 4 AEs were similar (HR: 1.17, 95% CI: 0.82-1.68, p=0.39).

However, among those stopping C cotrimoxazole the risks for grade 4 AEs were significantly higher (HR: 2.03, 95% CI: 0.98-4.18, p=0.05). This was mostly because of anaemia, with 12 cases in those who stopped compared to just two in those who continued.  Overall, the levels of haemoglobin were lower among those who stopped.

While there were no substantive differences over time in changes in CD4 count, weight and height, there was a tendency to a higher weight in those who continued. 

The researchers concluded, from this first randomised clinical trial in children with a background of bacterial and protozoan infections, that continuing cotrimoxazole after more than two years on ART is beneficial for HIV-infected children in Africa.

Following the presentation, a participant in the audience representing WHO confirmed that the cotrimoxazole prophylaxis guidelines would be revised this year.


Bwakura-Dangarembizi M et al. Randomized comparison of stopping vs. continuing cotrimoxazole prophylaxis among 758 HIV+ children on long-term ART: The Anti-Retroviral Research for Watoto trial. 20th Conference on Retroviruses and Opportunistic Infections, Atlanta, abstract 86, 2013.

View the abstract on the conference website.

A webcast of the session in which this research was presented, MTCT and HIV treatment in children, is available on the conference website.

NAM is partnering with gTt (Barcelona), GAT (Lisbon) and LILA (Como) to deliver the CROI 2013 bulletins, which have also been made possible thanks to support from Bristol-Myers Squibb. NAM’s wider conference news reporting services have been supported by Abbott, Boehringer Ingelheim, Janssen, Roche and ViiV Healthcare. The funders have no editorial control over the content of the materials.

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.